Federal Register / Vol. 73, No. 194 / Monday, October 6, 2008 / Notices 58239 

Trans No. Acquiring Acquired Entities 

No. 7 Ltd., Taiwan Branch. 

20081682 ....... GeNx36O Capital Partners, L.P ....... GSC Recovery IIA, L.P .................... Precision Partners, Inc. 

20081703 ....... AEP Industries Inc ............................ Atlantis Plastics, Inc ......................... Atlantis Plastic Films, Inc. 

Linear Films, Inc. 

20081711 ....... Ecopetrol S.A .................................... Chevron Corporation ........................ Union Oil Company of California. 

20081718 ....... Fortune Brands, Inc .......................... Pernod Ricard SA ............................. Cruzan Viril, Ltd. 

The Absolut Spirits Company, Inc. 

V&S Vin Spirit AB. 

TRANSACTIONS GRANTED EARLY TERMINATION—09/15/2008 

20080831 ....... Reed Elsevier PLC ........................... ChoicePoint Inc ................................ ChoicePoint Inc. 

20080832 ....... Reed Elsevier NV ............................. ChoicePoint Inc ................................ ChoicePoint Inc. 

20080987 ....... Fresenius Medical Care AG & Co. 

KGaA.

Daiichi Sankyo Company, Limited ... Luitpold Pharmaceuticals, Inc. 

20081648 ....... Kulicke and Sofia Industries ............. Orthodyne Electronics Corporation .. Orthodyne Electronics Corporation. 

20081666 ....... JDA Software Group, Inc ................. i2 Technologies, Inc ......................... i2 Technologies, Inc. 

TRANSACTIONS GRANTED EARLY TERMINATION—09/16/2008 

20081683 ....... The Middleby Corporation ................ TurboChef Technologies, Inc ........... TurboChef Technologies, Inc. 

20081684 ....... Johnson & Johnson .......................... SurgRx, Inc ....................................... SurgRx, Inc. 

20081695 ....... Eli Lilly and Company ....................... Monsanto Company ......................... Monsanto Company. 

20081706 ....... Orkla ASA ......................................... Benson Holdings, Inc ....................... Benson Industries LLC. 

20081720 ....... Assurant, Inc ..................................... General Electric Company ............... General Electric Company. 

20081729 ....... Alberto-Culver Company .................. The Procter & Gamble Company ..... Noxell Corporation. 

20081735 ....... Arbor Investments II, L.P .................. Bradshaw International, Inc .............. Bradshaw International, Inc.

20081737 ....... J.P. Morgan Chase & Co ................. X-Rite, Incorporated ......................... X-Rite, Incorporated. 

20081738 ....... The Hanover Insurance Group, Inc .. AIX Holdings, Inc .............................. AIX Holdings, Inc. 

20081742 ....... Covanta Holding Corporation ........... Ridgewood Electric Power Trust IV .. Indeck Maine Energy, LLC. 

TRANSACTIONS GRANTED EARLY TERMINATION—09/18/2008 

20081783 ....... Barclays PLC .................................... Lehman Brothers Holdings Inc., a 

debtor-in-possession.

LB 745 LLC. 

Lehman Brothers Inc. 

TRANSACTIONS GRANTED EARLY TERMINATION—09/19/2008 

20081665 ....... Owens & Minor, Inc .......................... Mr. George Burrows ......................... The Burrows Company. 

20081719 ....... Chesapeake Energy Corporation ..... Cinco County Barnet Shale, LLC ..... DDJET Limited LLP. 

20081743 ....... Covanta Holding Corporation ........... Ridgewood Electric Power Trust V .. Indeck Maine Energy, LLC. 

V20081746 ..... Riverside Capital Appreciation Fund 

V, L.P.

Commercial Markets Holdco, Inc ..... JohnsonDiversey Canada, Inc. 

JohnsonDiversey, Inc. 

FOR FURTHER INFORMATION CONTACT: 

Sandra M. Peay, Contact Representative 

or Renee Hallman, Contact 

Representative, Federal Trade 

Commission, Premerger Notification 

Office, Bureau of Competition, Room H– 

303, Washington, DC 20580, (202) 326– 

3100. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. E8–23330 Filed 10–3–08; 8:45 am] 

BILLING CODE 6750–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Declaration Under the Public 

Readiness and Emergency 

Preparedness Act 

October 1, 2008. 

AGENCY: Office of the Secretary (OS), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: Declaration pursuant to 

section 319F–3 of the Public Health 

Service Act (42 U.S.C. 247d–6d) to 

provide targeted liability protections for 

anthrax countermeasures based on a 

credible risk that the threat of exposure 

to Bacillus anthracis and the resulting 

disease constitutes a public health 

emergency. 

DATES: This notice and the attached 

declaration are effective as of the date of 

signature of the declaration. 

FOR FURTHER INFORMATION CONTACT: 

RADM W.C. Vanderwagen, Assistant 

Secretary for Preparedness and 

Response, Office of the Secretary, 

Department of Health and Human 

Services, 200 Independence Avenue, 

SW., Washington, DC 20201, Telephone 

(202) 205–2882 (this is not a toll-free 

number). 

HHS Secretary’s Declaration for 

Utilization of Public Readiness and 

Emergency Preparedness Act for 

Anthrax Countermeasures 

Whereas significant changes in the 

nature, regularity and degree of threats 

to health posed by the use of infectious 

agents as weapons of biological warfare 

have generated increased concern for 

the safety of the general American 

population particularly following the 

deliberate exposure of citizens in the 


jlentini on PROD1PC65 with NOTICES
58240 Federal Register / Vol. 73, No. 194 / Monday, October 6, 2008 / Notices 

United States to Bacillus anthracis (B. 

anthracis) spores in 2001 that 

demonstrated the ease of dissemination, 

infectivity, and mortality; 

Whereas the Secretary of Homeland 

Security has determined that B. 

anthracis and multi-drug-resistant B. 

anthracis present a material threat 

against the United States population, 

sufficient to affect national security; 

Whereas there are covered 

countermeasures to treat, identify, or 

prevent adverse health consequences or 

death from exposure to B. anthracis; 

Whereas such countermeasures, 

including vaccines, antimicrobials/ 

antibiotics, and antitoxins for preexposure and post-exposure prevention 

and treatment, diagnostics to identify 

such exposure, and additional 

countermeasures for treatment of 

adverse events arising from use of these 

countermeasures exist or may be the 

subject of research and/or development; 

Whereas such countermeasures may 

be used and administered in accordance 

with Federal contracts, cooperative 

agreements, grants, interagency 

agreements, and memoranda of 

understanding, and may also be used 

and administered at the Regional, State, 

and local level in accordance with the 

public health and medical response of 

the Authority Having Jurisdiction; 

Whereas, the possibility of 

governmental program planners 

obtaining stockpiles from private sector 

entities except through voluntary means 

such as commercial sale, donation, or 

deployment would undermine national 

preparedness efforts and should be 

discouraged as provided for in section 

319F–3(b)(2)(E) of the Public Health 

Service Act (42 U.S.C. 247d–6d(b)) (‘‘the 

Act’’); 

Whereas, immunity under section 

319F–3(a) of the Act should be available 

to governmental program planners for 

distributions of Covered 

Countermeasures obtained voluntarily, 

such as by (1) Donation; (2) commercial 

sale; (3) deployment of Covered 

Countermeasures from Federal 

stockpiles; or (4) deployment of 

donated, purchased, or otherwise 

voluntarily obtained Covered 

Countermeasures from State, local, or 

private stockpiles; 

Whereas, the extent of immunity 

under section 319F–3(a) of the Act 

afforded to a governmental program 

planner that obtains covered 

countermeasures except through 

voluntary means is not intended to 

affect the extent of immunity afforded 

other covered persons with respect to 

such covered countermeasures. 

Whereas, in accordance with section 

319F–3(b)(6) of the Act, I have 

considered the desirability of 

encouraging the design, development, 

clinical testing or investigation, 

manufacturing, labeling, distribution, 

formulation, packaging, marketing, 

promotion, sale, purchase, donation, 

dispensing, prescribing, administration, 

licensing, and use of such 

countermeasures with respect to the 

category of disease and population 

described in sections II and IV below, 

and have found it desirable to encourage 

such activities for the covered 

countermeasures; and 

Whereas, to encourage the design, 

development, clinical testing or 

investigation, manufacturing and 

product formulation, labeling, 

distribution, packaging, marketing, 

promotion, sale, purchase, donation, 

dispensing, prescribing, administration, 

licensing, and use of medical 

countermeasures with respect to the 

category of disease and population 

described in sections II and IV below, it 

is advisable, in accordance with section 

319F–3(a) and (b) of the Act, to provide 

immunity from liability for covered 

persons, as that term is defined at 

section 319F–3(i)(2) of the Act, and to 

include as such covered persons such 

other qualified persons as I have 

identified in section VI of this 

declaration; 

Therefore, pursuant to section 319F– 

3(b) of the Act, I have determined there 

is a credible risk that the threat of 

exposure of B. anthracis and the 

resulting disease constitutes a public 

health emergency. 

I. Covered Countermeasures (As 

Required by Section 319F–3(b)(1) of the 

Act) 

Covered Countermeasures are defined 

at section 319F–3(i) of the Act. At this 

time, and in accordance with the 

provisions contained herein, I am 

recommending the manufacture, testing, 

development, distribution, dispensing; 

and, with respect to the category of 

disease and population described in 

sections II and IV below, the 

administration and usage of anthrax 

countermeasures as defined in section 

IX below. The immunity specified in 

section 319F–3(a) of the Act shall only 

be in effect with respect to: (1) Present 

(see Appendix I) or future Federal 

contracts, cooperative agreements, 

grants, interagency agreements, or 

memoranda of understanding involving 

countermeasures that are used and 

administered in accordance with this 

declaration, and (2) activities authorized 

in accordance with the public health 

and medical response of the Authority 

Having Jurisdiction to prescribe, 

administer, deliver, distribute or 

dispense the Covered Countermeasure 

following a declaration of an emergency, 

as defined in section IX below. In 

accordance with section 319F–3(b)(2)(E) 

of the Act, for governmental program 

planners, the immunity specified in 

section 319F–3(a) of the Act shall be in 

effect to extent they obtain Covered 

Countermeasures through voluntary 

means of distribution, such as (1) 

Donation; (2) commercial sale; (3) 

deployment of Covered 

Countermeasures from Federal 

stockpiles; or (4) deployment of 

donated, purchased, or otherwise 

voluntarily obtained Covered 

Countermeasures from State, local, or 

private stockpiles. For all other covered 

persons, including other program 

planners, the immunity specified in 

section 319F–3(a) of the Act shall, in 

accordance with section 319F–3(b)(2)(E) 

of the Act, be in effect pursuant to any 

means of distribution. 

This declaration shall subsequently 

refer to the countermeasures identified 

above as ‘‘Covered Countermeasures.’’ 

This declaration shall apply to all 

Covered Countermeasures administered 

or used during the effective time period 

of the declaration. This declaration also 

shall apply to all Covered 

Countermeasures (see Appendix I) 

administered or used by or on behalf of 

the Department of Defense. 

II. Category of Disease (As Required by 

Section 319F–3(b)(2)(A) of the Act) 

The category of disease, health 

condition, or threat to health for which 

I am recommending the administration 

or use of the Covered Countermeasures 

is anthrax, which may result from 

exposure to B. anthracis. 

III. Effective Time Period (As Required 

by Section 319F–3(b)(2)(B) of the Act) 

With respect to Covered 

Countermeasures administered and 

used in accordance with present or 

future Federal contracts, cooperative 

agreements, grants, interagency 

agreements, or memoranda of 

understanding, the effective period of 

time of this Declaration commences on 

signature of the declaration and extends 

through December 31, 2015. 

With respect to Covered 

Countermeasures administered and 

used in accordance with the public 

health and medical response of the 

Authority Having Jurisdiction, the 

effective period of time of this 

Declaration commences on the date of a 

declaration of an emergency and lasts 

through and includes the final day that 

the emergency declaration is in effect 

including any extensions thereof. 


jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 73, No. 194 / Monday, October 6, 2008 / Notices 58241 

IV. Population (As Required by Section 

319F–3(b)(2)(C) of the Act) 

Section 319F–3(a)(4)(A) of the Act 

confers immunity to manufacturers and 

distributors of the Covered 

Countermeasure, regardless of the 

defined population. 

Section 319F–3(a)(3)(C)(i) of the Act 

confers immunity to covered persons 

who may be a program planner or 

qualified persons with respect to the 

Covered Countermeasure only if a 

member of the population specified in 

the declaration as persons who use the 

Covered Countermeasure or to whom 

such a Covered Countermeasure is 

administered, is in or connected to the 

geographic location specified in this 

declaration, or the program planner or 

qualified person reasonably could have 

believed that these conditions are met. 

The populations specified in this 

declaration are all persons who use a 

Covered Countermeasure or to whom a 

Covered Countermeasure is 

administered in accordance with this 

declaration, including, but not limited 

to: Department of Defense military 

personnel and supporting civilianemployee and contractor personnel; any 

person conducting research and 

development of Covered 

Countermeasures directly by the Federal 

government or pursuant to a contract, 

grant, or cooperative agreement with the 

Federal government; any person who 

receives a Covered Countermeasure 

from persons authorized in accordance 

with the public health and medical 

emergency response of the Authority 

Having Jurisdiction to prescribe, 

administer, deliver, distribute, or 

dispense the Covered Countermeasure, 

and their officials, agents, employees, 

contractors, and volunteers following a 

declaration of an emergency; any person 

who receives a Covered Countermeasure 

from a person authorized to prescribe, 

administer or dispense the 

countermeasure or who is otherwise 

authorized under an Emergency Use 

Authorization; any person who receives 

a Covered Countermeasure as an 

investigational new drug in human 

clinical trials being conducted directly 

by the Federal government or pursuant 

to a contract, grant, or cooperative 

agreement with the Federal government. 

V. Geographic Area (As Required by 

Section 319F–3(b)(2)(D) of the Act) 

Section 319F–3(a) of the Act applies 

to the administration and use of a 

Covered Countermeasure without 

geographic limitation. 

VI. Qualified Persons (As Required by 

Section 319F–3(i)(8)(B) of the Act) 

With regard to the administration or 

use of a Covered Countermeasure, 

Section 319F–3(i)(8)(A) of the Act 

defines the term ‘‘qualified person’’ as a 

licensed individual who is authorized to 

prescribe, administer, or dispense the 

Covered Countermeasure under the law 

of the State in which such Covered 

Countermeasure was prescribed, 

administered or dispensed. Additional 

persons who are qualified persons 

pursuant to section 319F–3(i)(8)(B) are 

the following: (1) Any person who is 

authorized to prescribe, administer, 

deliver, distribute or dispense Covered 

Countermeasures to Department of 

Defense military personnel and 

supporting civilian-employee and 

contractor personnel, (2) Any person 

authorized in accordance with the 

public health and medical emergency 

response of the Authority Having 

Jurisdiction to prescribe, administer, 

deliver, distribute or dispense Covered 

Countermeasures, and their officials, 

agents, employees, contractors and 

volunteers, following a declaration of an 

emergency, and (3) Any person 

authorized to prescribe, administer, or 

dispense Covered Countermeasures or 

who is otherwise authorized under an 

Emergency Use Authorization, 

including, but not limited to 

Department of Defense military 

personnel and supporting civilian 

employee and contractor personnel. 

VII. Additional Time Periods of 

Coverage After Expiration of 

Declaration (As Required by Section 

319F–3(b)(3)(B) of the Act) 

I have determined that, upon 

expiration of the time period specified 

in Section III above, an additional 

twelve (12) months is a reasonable 

period to allow for manufacturers and 

other covered persons to take such other 

actions as are appropriate to limit the 

administration or use of the Covered 

Countermeasure, and the liability 

protection of section 319F–3(a) of the 

Act shall extend for that period. Further, 

as to doses shipped by the CDC to the 

DoD pursuant to the DoD/CDC 

Interagency Agreement (IAA) dated 

March 10, 2008, an additional period of 

time of liability protection shall extend 

for as long as the SNS or its successor 

exists and the IAA remains in effect, 

plus, if the additional twelve (12) 

months following the time period in 

Section III above has expired, an 

additional twelve (12) months upon 

expiration of the IAA. 

VIII. Amendments 

This declaration has not previously 

been amended. Any future amendment 

to this declaration will be published in 

the Federal Register, pursuant to 

section 319F–3(b)(4) of the Act. 

IX. Definitions 

For the purpose of this declaration, 

including any claim for loss brought in 

accordance with section 319F–3 of the 

PHS Act against any covered persons 

defined in the Act or this declaration, 

the following definitions will be used: 

Administration of a Covered 

Countermeasure: As used in Section 

319F–3(a)(2)(B) of the Act includes, but 

is not limited to, public and private 

delivery, distribution, and dispensing 

activities relating to physical 

administration of the Covered 

Countermeasures to patients/recipients, 

management and operation of delivery 

systems, and management and operation 

of distribution and dispensing locations. 

Anthrax Countermeasure: Any 

vaccine; antimicrobial/antibiotic, other 

drug or antitoxin; or diagnostic or 

device to identify, prevent or treat 

anthrax or adverse events from such 

countermeasures (1) Licensed under 

section 351 of the Public Health Service 

Act; (2) approved under section 505 or 

section 515 of the Federal Food, Drug, 

and Cosmetic Act (FDCA); (3) cleared 

under section 510(k) of the FDCA; (4) 

authorized for emergency use under 

section 564 of the FDCA ; (5) used under 

section 505(i) of the FDCA or section 

351(a)(3) of the PHS Act, and 21 CFR 

Part 312; or (6) used under section 

520(g) of the FDCA and 21 CFR part 

812. 

Authority Having Jurisdiction: The 

public agency or its delegate that has 

legal responsibility and authority for 

responding to an incident, based on 

political or geographical (e.g., city, 

county, tribal, State, or Federal 

boundary lines) or functional (e.g., law 

enforcement, public health) range or 

sphere of authority. 

Covered persons: As defined at 

section 319F–3(i)(2) of the Act include 

the United States, manufacturers, 

distributors, program planners, and 

qualified persons. The terms 

‘‘manufacturer,’’ ‘‘distributor,’’ 

‘‘program planner,’’ and ‘‘qualified 

person’’ are further defined at sections 

319F–3(i)(3), (4), (6), and (8) of the Act. 

Declaration of an emergency: A 

declaration by any authorized local, 

regional, State, or federal official of an 

emergency specific to events that 

indicate an immediate need to 

administer and use anthrax 

countermeasures, with the exception of 


jlentini on PROD1PC65 with NOTICES
58242 Federal Register / Vol. 73, No. 194 / Monday, October 6, 2008 / Notices 

a federal declaration in support of an 

emergency use authorization under 

section 564 of the FDCA unless such 

declaration specifies otherwise. 

This first day of October, 2008. 

Michael O. Leavitt, 

Secretary of Health and Human Services. 

APPENDIX I—LIST OF U.S. GOVERNMENT CONTRACTS

Contract Manufacturer Covered countermeasure PL 85–804 

coverage* 

HHSO100200500007C ........................ Cangene ............................................. Anthrax immune globulin—AIG .............................. No. 

HHSO100200500006C ........................ HGS ................................................... Anthrax monoclonal antibody-ABThrax ................. No. 

HHSO100200600019C ........................ Emergent Biodefense Operations ...... BioThrax (Anthrax Vaccine Adsorbed, AVA) ......... Yes. 

HHSO100200700037C ........................ Emergent Biodefense Operations ...... BioThrax (Anthrax Vaccine Adsorbed, AVA) ......... No. 

W9113M–04–D–0002 .......................... BioPort (Emergent Biosolutions) ........ BioThrax (Anthrax Vaccine Adsorbed, AVA) ......... Yes. 

DAMD 17–97–D–00003 ....................... BioPort (Emergent Biosolutions) ........ BioThrax (Anthrax Vaccine Adsorbed, AVA) Shipping.Yes. 

HHSN 272200700035C ....................... Elusys ................................................. Anthrax monoclonal antibody—ETI–204 ............... No. 

HHSN 272200700033C ....................... Pharmathene ...................................... Anthrax monoclonal antibody—Valortim ................ No. 

HHSN 272200700034C ....................... Emergent BioSolutions ...................... Anthrax immune globulin—AIG .............................. No. 

NO1–A1–30052 .................................... Avecia (Pharmathene) ....................... Recombinant protective antigen (rPA) anthrax 

vaccine.

No. 

V797P–5777x ....................................... Shering Corp. ..................................... Cipro 250mg/5ml; 100ml suspension .................... No. 

V797P–5977x ....................................... Cobalt Pharmaceuticals ..................... Cipro 500mg tablets ............................................... No. 

V797P–5941x ....................................... Blu Pharmaceuticals .......................... Doxycycline 100mg tablets .................................... No. 

V797P–5883x ....................................... Pfizer, Inc ........................................... Doxycycline 25mg/5ml suspension 60ml ............... No. 

V797P–5669x ....................................... Abraxis Bioscience, Inc ...................... Doxycycline 100mg vial IV ..................................... No. 

V797–DSNS–8002 ............................... Sandoz, Inc ........................................ Amoxicillin 500mg capsules ................................... No. 

V797–DSNS–8002 ............................... Sandoz, Inc ........................................ Amoxicillin 400mg/5ml; 100ml suspension ............ No. 

V797BPA0015 ...................................... Bedford Labs ...................................... Rifampin 600mg vial IV .......................................... No. 

V797P–5396x ....................................... Hospira ............................................... Clindamycin 150mg/ml 6ml vial IV ......................... No. 

V797P–5669x ....................................... Abraxis Bioscience, Inc ...................... Vancomycin 1 g vial IV .......................................... No. 

V797P–1020x ....................................... McKesson .......................................... Penicillin GK 20 million unit vial IV ........................ No. 

V797P–5387x ....................................... Johnson and Johnson Healthcare ..... Levofloxacin 5mg/ml 150ml bag IV ........................ No. 

* Status of indemnification coverage under P.L. 85–804 (An Act to authorize the making, amendment and modification of contracts to facilitate 

the national defense.) 

[FR Doc. E8–23547 Filed 10–1–08; 4:15 pm] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Determination and Declaration 

Regarding Emergency Use of 

Doxycycline Hyclate Tablets 

Accompanied by Emergency Use 

Information 

AGENCY: Office of the Secretary (OS), 

HHS. 

ACTION: Notice. 

SUMMARY: The Secretary of the 

Department of Health and Human 

Services (HHS) is issuing this notice 

pursuant to section 564(b)(4) of the 

Federal Food, Drug, and Cosmetic Act 

(FFDCA), 21 U.S.C. 360bbb–3(b)(4), to 

justify the emergency use of 

doxycycline hyclate tablets 

accompanied by emergency use 

information, contained in emergency 

kits for eligible United States Postal 

Service (USPS) Cities Readiness 

Initiative (CRI) participants and their 

household members in advance of a 

potential attack involving Bacillus 

anthracis. Bacillus anthracis is a 

biological agent known to cause 

anthrax. The Secretary, HHS, provides 

notice of the determination of the 

Secretary of Homeland Security on 

September 23, 2008 that there is a 

significant potential for a domestic 

emergency involving a heightened risk 

of attack with a specified biological, 

chemical, radiological, or nuclear agent 

or agents—in this case, Bacillus 

anthracis, although there is no current 

domestic emergency involving anthrax, 

no current heightened risk of an anthrax 

attack, and no credible information 

indicating an imminent threat of an 

attack involving Bacillus anthracis. The 

Secretary also provides notice that, on 

the basis of such determination, he has 

declared an emergency justifying the 

authorization of emergency use of 

doxycycline hyclate tablets 

accompanied by emergency use 

information subject to the terms of any 

authorization issued by the Food and 

Drug Commissioner under 21 U.S.C. 

360bbb–3(a). 

DATES: This Notice and referenced HHS 

declaration are effective as of October 1, 

2008. 

FOR FURTHER INFORMATION CONTACT: 

RADM W.C. Vanderwagen, M.D., 

Assistant Secretary for Preparedness 

and Response, Office of the Secretary, 

Department of Health and Human 

Services, 200 Independence Avenue, 

SW., Washington, DC 20201, Telephone 

(202) 205–2882 (this is not a toll free 

number). 

SUPPLEMENTARY INFORMATION: 

I. Background 

The CRI, begun in 2004, is a federally 

supported effort to prepare 72 major 

U.S. metropolitan areas to effectively 

respond to a large-scale bioterrorist 

event by dispensing antibiotics to their 

entire identified population within 48 

hours of the decision to do so. Over the 

past several years, HHS and the USPS 

have developed and tested in three U.S. 

cities—Seattle, Philadelphia and 

Boston—the ability of letter carriers to 

quickly deliver door-to-door a few days’ 

worth of antibiotics to residential 

addresses. This quick-strike capability is 

intended to buy time for State and local 

public health authorities to set up 

points of dispensing for further 

provision of antibiotics across the 

community, as needed. 

Under Section 564 of the FFDCA, the 

Secretary of Homeland Security may 

determine that there is a domestic 

emergency, or a significant potential for 

a domestic emergency, involving a 

heightened risk of attack with a 

specified biological chemical, 

radiological or nuclear agent or agents. 


jlentini on PROD1PC65 with NOTICES